3721 Valley Centre Drive
Tel: 888-969-RTRX (7879)
Even with the challenges all of us are facing as a result of COVID-19, Retrophin continues to come together as an organization to live our mission each day to support our patients and invest in our capabilities for the future. At the center of these efforts are our people. Retrophin remains committed to preventing interruption of our clinical programs, providing unwavering patient support and ensuring delivery of therapies to our patients. Moments like this are when our patients need us the most.
If you want to join a team that now more than ever lives its mission to the fullest extent, please review our current opportunities and apply to positions that may be of interest to you.
Retrophin is continuing to hire for all open roles with all interviewing and onboarding done virtually due to COVID-19.
Everyone new to the team, along with our current staff, will temporarily work from home until it is safe to return to our offices.
At Retrophin, our number one priority will always be the patients we serve - they are “why” we come to work each day. Our Why is ingrained into our culture and is paramount to “what” we do every day and “how” we do it to achieve our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. By working hard, supporting our team members and living our values of Accountability, Entrepreneurial Spirit, Integrity, Patient Focus, Scientific Excellence and Teamwork, we strive to help our organization succeed and pursue our vision - to become a preeminent, global and fully-integrated biopharmaceutical company within the rare disease community that is dedicated to giving patients a chance and providing hope.
Our pipeline features late-stage development programs targeting rare diseases with significant unmet medical needs including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. In partnership with leaders in patient advocacy and government research, we are also working to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, rare conditions with no approved treatment options. Our R&D efforts are supported by revenues from our four commercial products Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin) and THIOLA EC™ (tiopronin) delayed-release tablets.
Through our portfolio of approved products and promising pipeline focused on hepatology, nephrology and neurology, we strive to help people achieve the best possible outcomes today and tomorrow. But most importantly, it is the commitment of our experienced, knowledgeable and compassionate team members, who put patients at the center of everything they do, that truly matters.
210 articles with Retrophin
Travere Therapeutics will also begin trading under the new ticker symbol, “TVTX” on the Nasdaq Global Select Market beginning on Nov. 19.
Retrophin Inc., (NASDAQ: RTRX) today announced that the Company has changed its global corporate name to Travere Therapeutics, Inc. This new name reflects the Company’s steadfast dedication to helping people
Retrophin Completes Acquisition of Orphan TechnologiesAddition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases
Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU).
Retrophin, Inc. announced that Company management will present at the following upcoming virtual investor conferences in November and December
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21
OT-58 is Orphan’s novel investigational enzyme replacement therapy. It is currently in Phase I/II development for classical HCU, a rare metabolic disorder marked by increased levels of plasma homocysteine.
Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a definitive agreement to acquire Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU)
Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Conference Call Information Date: Thursday, November 5, 2020 Time: 4:30 p.m. ET Dial-in numbers: +1 (855) 219-9
Retrophin, Inc. announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 58,750 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 37,500 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 21,250 shares of its common stock.
Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined. The Company and its collaborators will also feature encore presentations of preclinical data supporting the potential f
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA NephropathyTopline data from 36-week proteinuria endpoint anticipated in third quarter of 2021
Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy (IgAN).
Retrophin, Inc. announced that Company management will participate in the following upcoming virtual investor conferences in August
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021
Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the U.S. financial markets.
Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 10:00 a.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/events and an archived replay will be accessible for up to 30 days. About Retrophin Retrophin is a biopharmaceutical company specializing in identif
Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions. All of the shares are being offered by Retrophin
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 p.m. ET.
Retrophin, Inc. reported its first quarter 2020 financial results and provided a corporate update.
Retrophin, Inc. announced it will report first quarter 2020 financial results on Monday, May 11, 2020 after the close of the U.S. financial markets.
4/15/2020The COVID-19 battle dominates the news, but it doesn’t constitute all the news. Here’s what several Southern California Biotech Beach companies are doing that you might have missed.